SENS Research Foundation works to develop, promote, and ensure widespread access to therapies that cure and prevent the diseases and disabilities of aging by comprehensively repairing the damage that builds up in our bodies over time. We are redefining the way the world researches and treats age-related ill health, while inspiring the next generation of biomedical scientists.

Discover the science behind our strategies to extend a healthy lifespan.

Training a new generation of scientists to tackle the roots of age-related disease.

Keep up to date on SRF’s latest news and activities.

SRF is delighted to announce the launch of Underdog Pharmaceuticals, Inc., and the completion of its $3.95 million seed round led by Michael Greve’s Kizoo Technology Capital.

Built from a flagship intramural program at SRF, and co-founded by our former CEO Mike Kope and former VP of Research Dr. Matthew O’Connor, Underdog will advance the development of damage-repair treatments to reverse atherosclerosis and other age-related diseases.

Of all the challenges in cell therapy, replacement of neurons in the neocortex is both the most important and perhaps the most formidable. Only recently have any researchers succeeded in integrating new neurons into this area of the brain. However, the vast majority of transplanted cells in these cases have failed to survive, and the few survivors have achieved only limited function and integration into existing circuits. SRF is now supporting Dr. Jean Hébert’s work to advance two innovative strategies to address different aspects of this challenge.

The Postbaccalaureate Fellowship Program offers recent graduates the opportunity to combat the diseases of aging, while training under the supervision of world-class scientific mentors.

Program Deadline

12 pm PST on February 17, 2020

Don’t miss out!

The latest SRF news:

Staging Aging

A team including SRF protégé Stuart Calimport and several members of our Research Advisory Board argues in Science that the systematic classification and staging of aging-related pathology (as is currently done for cancer) should dramatically accelerate the deployment of rejuvenation therapies.

Job Opportunity: Research Assistant (ImmunoSENS)

We are seeking a full-time Research Assistant to join the ImmunoSENS group at our Research Center in Mountain View, California, for a project geared toward developing therapies to restore the ability of the aging immune system to clear senescent cells.

Rejuvenation Now!

The Forever Healthy Foundation has launched a new “Rejuvenation Now” initiative, designed to identify rejuvenation therapies that are available right now and evaluate their risks and benefits. Analyses of NAD+ Restoration Therapy and Fisetin Senolytic Therapy are now available to read.

SciFuture Interview

In conversation with Adam Ford, Dr. Aubrey de Grey explains how recent extraordinary results with senolytic drugs suggest that the milestone of “Robust Mouse Rejuvenation” – a key step towards comprehensively undoing human aging – could be as little as three years away.

Read More »

More Cryptocurrencies Added

SENS Research Foundation is now able to accept donations in Zcash (ZEC), in addition to eight other major cryptocurrencies: Bitcoin, Bitcoin Cash, Ethereum, Ethereum Classic, Litecoin, 0x (ZRX), USD Coin, and BAT. Visit the donate page for more information!

Read More »

Vitalik’s $350,000 Donation

We’re grateful to cryptocurrency pioneer Vitalik Buterin for once again choosing to support SENS Research Foundation, with a generous donation of $350,000 in Ethereum towards our End of Year campaign to Reimagine Aging.

Read More »

Target Prioritization of Tissue Crosslinking

The Babraham Institute Principal Investigator: Jonathan ClarkResearch Team: Melanie Stammers As discussed in the project summary for “Glucosepane Crosslinks and Undoing Age-Related Tissue Damage”, adventitious crosslinking of collagen (and elastin) contributes to the slow stiffening of our arteries and other tissues

Read More »

Use of this Web site constitutes acceptance of the Terms of Use and Privacy Policy.

© 2019 SENS Research Foundation – ALL RIGHTS RESERVED

Thank you for Subscribing to the SENS Research Foundation Newsletter.

You can also


You can